All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Legend Biotech, Pfizer, and Roche. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Why do we not see curative CAR T-cell therapy in MM (compared to DLBCL and ALL)?
Featured:
Noopur RajeDuring the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Noopur Raje, Massachusetts General Hospital, Boston, US, about chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM).
Why do we not see curative CAR T-cell therapy in MM (compared to DLBCL and ALL)?
Recent data from the currently ongoing KarMMa trial has shown a progression-free survival (PFS) of only 10.5 months for all participants. Patients that achieved a stringent complete response reached a PFS of approximately 20 months.
Therefore, we asked, Why do we not see curative CAR T-cell therapy in MM (compared to diffuse large B-cell lymphoma [DLBCL] and acute lymphoblastic leukemia [ALL])?
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with MGUS/smoldering MM do you see in a month?